What are my initial treatment options for Prostate Cancer, and should targeted or immunotherapy based on biomarkers...

Initial Treatment Options for Prostate Cancer

I'd be happy to help you understand the treatment landscape for prostate cancer. To give you the most relevant information, let me start with some important context about how doctors approach this decision.

How Doctors Think About Initial Treatment

Your initial treatment depends heavily on stage (how far the cancer has spread) and risk level. PSA (prostate-specific antigen) is one important marker, but it's just one piece of the puzzle. Doctors also consider:

• Whether cancer is localized (confined to the prostate) or metastatic (spread to other areas)
• Gleason score (how aggressive the cancer cells look under a microscope)
• Other biomarkers and genetic mutations
• Your overall health and life expectancy

General Treatment Approaches That Exist

For Localized Prostate Cancer (early-stage):

• Active surveillance — careful monitoring if cancer is low-risk
• Surgery (prostatectomy — removal of the prostate)
• Radiation therapy (external beam or brachytherapy)
• Hormone therapy (androgen deprivation therapy or ADT) — blocks testosterone that fuels prostate cancer growth

For Advanced/Metastatic Prostate Cancer (spread to other areas):

• Hormone therapy — first-line treatment, often very effective initially
• Chemotherapy — drugs like docetaxel or cabazitaxel for hormone-resistant disease
• Radiopharmaceuticals — newer treatments like Pluvicto that target prostate cancer cells specifically
• Targeted therapies — for specific genetic mutations (like BRCA1/2 or ATM mutations)
• Immunotherapy — emerging option, though less commonly used as initial treatment

---

About PSA and Biomarkers

PSA alone is NOT typically used to select between targeted or immunotherapy approaches. Here's why:

According to the NCCN Guidelines for Prostate Cancer, PSA is primarily a monitoring tool — it helps track how well treatment is working over time. Rising PSA after treatment suggests the cancer may be becoming resistant.

More actionable biomarkers include:

• BRCA1/2 mutations — can make cancers responsive to PARP inhibitors (drugs that prevent cancer cells from repairing DNA damage)
• ATM mutations — also associated with PARP inhibitor sensitivity
• Mismatch repair deficiency — may indicate immunotherapy responsiveness
• PSMA expression — determines if radiopharmaceuticals like Pluvicto are appropriate

---

Real-World Example: Advanced Prostate Cancer Case

The CancerPatientLab Molecular Tumor Board discussion with Dr. [removed] Davis (a stage 4 metastatic prostate cancer patient) illustrates this complexity. Dr. [removed] had genetic testing showing ATM and BRCA1 mutations, which initially seemed promising for PARP inhibitors. However, the mutations were present at very low frequency (below 25%), making them "not actionable" — meaning they weren't present in enough cancer cells to reliably respond to PARP inhibitor treatment.

This case shows that having a mutation isn't enough — doctors need to understand how prevalent it is in your tumor to predict treatment response.

---

Questions to Ask Your Oncologist

Based on your situation, here are specific questions that will help guide your treatment decision:

1. "What is my cancer stage, and what is my risk level (low, intermediate, or high)?" — This determines whether you need aggressive treatment or can monitor carefully.

2. "Have I had genetic testing (like Foundation One or similar)? If so, what mutations were found, and at what frequency?" — This reveals whether targeted therapies like PARP inhibitors might work.

3. "What is my Gleason score, and what does that tell us about how aggressive my cancer is?" — This helps predict how quickly it might progress.

4. "Should I have imaging like PSMA-PET or FDG-PET scans to see where the cancer has spread?" — This affects treatment selection (for example, PSMA-positive disease may respond to radiopharmaceuticals).

5. "Are there clinical trials available for my specific stage and biomarker profile?" — Trials may offer newer options not yet standard.

6. "If hormone therapy is recommended, how long should I expect it to work, and what's the plan when resistance develops?" — Prostate cancer often becomes hormone-resistant over time, so understanding the sequence of treatments matters.

---

Key Takeaway

PSA alone should not drive the choice between targeted therapy and immunotherapy. Instead, your doctor will consider your stage, risk level, and specific genetic mutations. According to NCCN Guidelines, most patients with newly diagnosed prostate cancer start with hormone therapy (ADT), surgery, or radiation — depending on stage. Targeted therapies and immunotherapy typically come into play later, especially for advanced or treatment-resistant disease, and only when specific biomarkers support their use.

Your oncologist will determine the most appropriate approach for YOUR case based on your complete clinical picture, not just PSA levels.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.